Epigenetic silencing schlafen-11 sensitizes esophageal cancer to ATM inhibitor

Figure 4 Schlafen-11 silencing sensitized esophageal squamous cell carcinoma cells to AZD0156. A: MTT assay to evaluate the sensitivity of esophageal squamous cell carcinoma (ESCC) cells to AZD0156 under the treatment of low dose cisplatin, data are representative of three independent experiments; B: Representative colony formation assay under the treatment of low dose cisplatin, AZD0156 and combined mini-dose cisplatin with AZD0156 for 14 d in ESCC cells, each experiment was repeated in triplicate, the average normalized colony efficiency was indicated by a bar diagram, statistical significance was analyzed by t test (^bP < 0.01, ^cP < 0.001, ^dP < 0.0001); C: The protein levels of ATM/CHK2 signaling and γ-H2AX in ESCC cells under the treatment of low dose cisplatin, AZD0156 and combined cisplatin with AZD0156 in ESCC cells. KO: Knockout; β-actin: Internal control.